 - bilirubin 2 mgdL: At two weeks from biliary decompression, if the subjects serum bilirubin remains greater than 2, but has demonstrated a progressive decline, the subject may be enrolled in the trial and appropriate modification and dose adjustments will be made to the predicted regimen. Eligibility and treatment assignments of subjects whose bilirubin levels remain elevated above 2, without demonstrating a downward trend, will be determined at the discretion of the trial principal investigators. In subjects with Gilberts syndrome with total bilirubin 2, measure direct bilirubin, and if direct bilirubin is 1.5 x ULN, the patient will be considered eligible. 